Deb Schrag, MD, MPH, FASCO
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO,as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect upon the conclusion of the 2026 ASCO Annual Meeting.
Dr. Schrag, a gastrointestinal medical oncologist, is the George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) and Professor of Medicine at Weill Cornell Medical College in New York. She is a population scientist and health services researcher who has worked to improve the quality, effectiveness, and experience of cancer care. Before assuming her current roles, Dr. Schrag served as Chief of the Division of Population Sciences at Dana-Farber Cancer Institute and as Professor of Medicine at Harvard Medical School in Boston.
Over her 2-decade career, Dr. Schrag has partnered with local, state, and federal agencies to design cancer control plans to advance population health. As a long-time ASCO member, Dr. Schrag has served in a variety of volunteer leadership roles, including as a member of the ASCO Board of Directors from 2008 to 2012. She chaired the Health Services Committee and worked on numerous other committees and task forces, including the Annual Meeting Scientific Program Committee, Quality and Practice Guidelines Committee, and the Joint Special Awards Selection Committee, and served as a mentor for ASCO’s Leadership Development Program.
“ASCO is at the forefront of cancer care and empowers the global oncology community by bringing us together to share knowledge, drive innovation and discovery, and join forces to improve outcomes for people with cancer everywhere,” said Dr. Schrag. “I thank ASCO’s members for trusting me with this important responsibility and look forward to partnering with them to advance the Society’s strategic plan and championing our shared values to accelerate progress.”
ASCO’s New Board Members
ASCO’s Board of Directors comprises oncology leaders who are elected to positions reflecting various specialties within the field. The following physicians will begin 4-year terms as members of ASCO’s Board of Directors starting in June 2026.
Piyush Srivastava, MD, FASCO,has been elected to a Designated Community Oncologist seat. Dr. Srivastava is a gastrointestinal oncologist and palliative care physician at Kaiser Permanente with extensive leadership experience within ASCO. He has served as Chair of the Clinical Practice Committee, Government Relations Committee, and Clinician Well-Being Task Force, and currently chairs the Practice Quality Improvement Steering Group. He also serves on the Health Policy Committee and is a long-standing faculty member and coach for ASCO’s Quality Training Program.
C.S. Pramesh, MBBS, MS, FRCS, has been elected to a Designated International Oncologist seat. Dr. Pramesh is Director at Tata Memorial Hospital, Convener at the National Cancer Grid, and a Professor in the Division of Thoracic Surgical Oncology at Tata Memorial Centre in Mumbai, India. He is also a Visiting Professor in the Division of Cancer Studies, Faculty of Life Sciences and Medicine at King’s College London, and on the academic faculty at the Institute of Cancer Policy, King’s Health Partners Integrated Cancer Centre, United Kingdom. Dr. Pramesh has served as a member of various ASCO volunteer groups, including the International Affairs Committee, the Annual Meeting Scientific Program Committee, the Multidisciplinary Cancer Management Courses Working Group, and the International Education Steering Group.
Karyn A. Goodman, MD, MS, FASTRO, FACR, FASCO, has been elected to the Designated Radiation Oncologist seat. Dr. Goodman is a Professor and Vice Chair of Radiation Oncology with a dual appointment as Professor of Medicine in the Division of Hematology and Oncology at the Icahn School of Medicine at Mount Sinai in New York. She serves as the Associate Director of Clinical Research in the Tisch Cancer Institute. She has served as a member of various ASCO volunteer groups, including the Annual Meeting Scientific Program Committee, among others.
W. Kimryn Rathmell, MD, PhD, FASCO, has been elected to an Undesignated Member seat. Dr. Rathmell is the Chief Executive Officer of the Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus. She has served in a multitude of ASCO volunteer roles, including as Chair of the Nominating Committee and as a member of several groups, including the Annual Meeting Education Committee, Career Development Committee, and Ethics Committee. She is also a graduate of ASCO’s Leadership Development Program.
Visit ASCO.org for information on additional leadership news.
